| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
97,871,000 |
| Market
Cap: |
902.37(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.66 - $22.03 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 20.2 |
| Insider 6 Months : 20.2 |
| Insider 3/6 Months : 40.8 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile 89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Co.'s primary product candidate, pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia. FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. FGF21 analogs represent a class of drugs to treat NASH, because they not only address the liver manifestations, but also have an effect on the multiple co-morbidities that worsen NASH.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,350,000 |
1,350,000 |
1,350,000 |
7,862,717 |
| Total Buy Value |
$20,722,500 |
$20,722,500 |
$20,722,500 |
$80,687,796 |
| Total People Bought |
1 |
1 |
1 |
2 |
| Total Buy Transactions |
1 |
1 |
1 |
5 |
| Total Shares Sold |
57,195 |
107,195 |
154,628 |
206,908 |
| Total Sell Value |
$623,326 |
$1,183,326 |
$2,078,063 |
$2,842,845 |
| Total People Sold |
1 |
1 |
4 |
5 |
| Total Sell Transactions |
2 |
3 |
7 |
15 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Waisbourd Ram |
See Remarks |
• – – |
2021-02-16 |
4 |
OE |
$1.93 |
$13,510 |
D/D |
7,000 |
7,000 |
|
- |
|
| Waisbourd Ram |
See Remarks |
• – – |
2021-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
4,000 |
|
- |
|
| Palekar Rohan |
Chief Executive Officer |
• • – |
2021-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Martins Ryan |
Chief Financial Officer |
• – – |
2021-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
7,500 |
|
- |
|
| Mansbach Harry H |
Chief Medical Officer |
• – – |
2021-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Le-Nguyen Quoc |
See Remarks |
• – – |
2021-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Waisbourd Ram |
See Remarks |
• – – |
2021-01-19 |
4 |
AS |
$21.16 |
$148,120 |
D/D |
(7,000) |
0 |
|
-10% |
|
| Waisbourd Ram |
See Remarks |
• – – |
2021-01-19 |
4 |
OE |
$1.93 |
$13,510 |
D/D |
7,000 |
7,000 |
|
- |
|
| Waisbourd Ram |
See Remarks |
• – – |
2020-12-16 |
4 |
AS |
$27.04 |
$189,280 |
D/D |
(7,000) |
0 |
|
0% |
|
| Waisbourd Ram |
See Remarks |
• – – |
2020-12-16 |
4 |
OE |
$1.93 |
$13,510 |
D/D |
7,000 |
7,000 |
|
- |
|
| Le-Nguyen Quoc |
See Remarks |
• – – |
2020-11-16 |
4 |
AS |
$28.11 |
$127,844 |
D/D |
(4,548) |
0 |
|
-16% |
|
| Le-Nguyen Quoc |
See Remarks |
• – – |
2020-11-16 |
4 |
OE |
$3.11 |
$14,144 |
D/D |
4,548 |
4,548 |
|
- |
|
| Grunberg Gregory |
Director |
– • • |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
850 |
850 |
|
- |
|
| Grunberg Gregory |
Director |
– • • |
2020-11-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(850,000) |
1,750,877 |
|
- |
|
| Waisbourd Ram |
COO and Chief Business Officer |
• – – |
2020-11-16 |
4 |
AS |
$27.39 |
$191,730 |
D/D |
(7,000) |
0 |
|
-16% |
|
| Waisbourd Ram |
COO and Chief Business Officer |
• – – |
2020-11-16 |
4 |
OE |
$1.93 |
$13,510 |
D/D |
7,000 |
7,000 |
|
- |
|
| Enright Patrick G |
10% Owner |
– – • |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
I/I |
5,944 |
891 |
|
- |
|
| Enright Patrick G |
10% Owner |
– – • |
2020-11-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(850,000) |
1,750,877 |
|
- |
|
| Naschitz Anat |
Director |
– • • |
2020-09-21 |
4 |
S |
$28.00 |
$7,700,000 |
I/I |
(275,000) |
1,864,721 |
|
13% |
|
| Orbimed Israel Gp Ii, L.p. |
Director |
– • • |
2020-09-21 |
4 |
S |
$28.00 |
$7,700,000 |
I/I |
(275,000) |
1,864,721 |
|
13% |
|
| Shah Rajeev M. |
Director |
– • • |
2020-09-17 |
4 |
B |
$28.00 |
$36,400,000 |
I/I |
1,300,000 |
4,736,214 |
2.25 |
-18% |
|
| Grunberg Gregory |
Director |
– • • |
2020-07-10 |
4 |
B |
$27.50 |
$2,999,975 |
I/I |
109,090 |
2,600,877 |
2.25 |
-19% |
|
| Enright Patrick G |
10% Owner |
– – • |
2020-07-10 |
4 |
B |
$27.50 |
$2,999,975 |
I/I |
109,090 |
2,600,877 |
1.5 |
-19% |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2020-07-08 |
4 |
B |
$27.50 |
$7,562,500 |
I/I |
275,000 |
3,436,214 |
1.5 |
-14% |
|
| Naschitz Anat |
Director |
– • • |
2019-11-13 |
4 |
A |
$0.00 |
$0 |
I/I |
2,555,716 |
2,002,221 |
|
- |
|
190 Records found
|
|
Page 7 of 8 |
|
|
0.36 (4.06%) 
